Albany, NY -- (ReleaseWire) -- 05/07/2014 -- “Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free Survival and Targeted Therapies”. The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission.
View Full Report with TOC at: http://www.researchmoz.us/ovarian-cancer-therapeutics-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-survival-and-targeted-therapies-report.html
However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.
The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS. In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS – olaparib, Vynfinit and trebananib, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA.
In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period. As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020. Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.
Browse More Reports from GBI Research Publisher at: http://www.researchmoz.us/publisher/gbi-research-2.html
Reasons to Buy:-
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.
Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.
Breast Cancer Therapeutics in Asia-Pacific Markets to 2020
Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options’, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%. Browse Full Report with TOC at: http://www.researchmoz.us/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-report.html
HIV Therapeutics in Major Developed Market to 2019
The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. Browse Full Report with TOC at: http://www.researchmoz.us/hiv-therapeutics-in-major-developed-market-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth-report.html
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948